These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31841104)

  • 1. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esketamine clinical trials: reply to Maju
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2020 Apr; 29():e122. PubMed ID: 32345395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esketamine Nasal Spray for Treatment-Resistant Depression.
    Fantasia HC
    Nurs Womens Health; 2020 Jun; 24(3):228-232. PubMed ID: 32387141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 6. Esketamine for treatment resistant depression.
    Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
    Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 10. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
    Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Food and Drug Administration approval of esketamine and brexanolone.
    Cristea IA; Naudet F
    Lancet Psychiatry; 2019 Dec; 6(12):975-977. PubMed ID: 31680013
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
    Nikayin S; Rhee TG; Cunningham ME; de Fontnouvelle CA; Ostroff RB; Sanacora G; Wilkinson ST
    JAMA Psychiatry; 2022 Jul; 79(7):736-738. PubMed ID: 35544190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal esketamine for depression: Not so special K.
    Rosenman S
    Australas Psychiatry; 2022 Aug; 30(4):533-534. PubMed ID: 35491953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
    Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M; Bartova L; Kasper S
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):440-445. PubMed ID: 32570275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.
    Kim J; Farchione T; Potter A; Chen Q; Temple R
    N Engl J Med; 2019 Jul; 381(1):1-4. PubMed ID: 31116916
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.